510(k) device
PERLA® Posterior Occipito-Cervico-Thoracic Fixation System
Spineart · Posterior Cervical Screw System (NKG, Class II) · First FDA decision Jan 25, 2016, newest May 1, 2020Degenerative disc disease and spinal stenosis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
510(k) pathway
Device trials
0
Naming "PERLA"
MAUDE reports
16
Brand "PERLA", since 2015
PubMed studies
97
Mentioning "PERLA"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing PERLA® Posterior Occipito-Cervico-Thoracic Fixation System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
K200571 · Decided May 1, 2020 · 58 days after receipt
Device type: Posterior Cervical Screw System (NKG) · Orthopedic Surgery
K190071 · Decided Feb 25, 2019 · 41 days after receipt
Device type: Posterior Cervical Screw System (NKG) · Orthopedic Surgery
K153386 · Decided Jan 25, 2016 · 63 days after receipt
Device type: Posterior Cervical Screw System (NKG) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "PERLA", any status and sponsor, newest update first.
No registered device study names "PERLA".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "PERLA", and for the whole product code for context.
This brand
16 reports: 11 malfunction, 4 injury, 0 death
Whole product code NKG
2,234 reports: 765 malfunction, 1,452 injury, 15 death
Newest reports for this brand
- Perla TLInjury
3007728266-2026-00023 · Received Sep 9, 2026
Device type: Thoracolumbosacral Pedicle Screw System (NKB)
Device problem as coded: Migration or Expulsion of Device
Patient problem as coded: Pain
- PERLA TLOther
3007728266-2026-00022 · Received Jul 28, 2026 · Event dated Jul 21, 2026
Device type: Thoracolumbosacral Pedicle Screw System (NKB)
Device problem as coded: Break
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- PERLA TLInjury
3007728266-2026-00021 · Received Jul 22, 2026 · Event dated Jul 15, 2026
Device type: Thoracolumbosacral Pedicle Screw System (NKB)
Device problem as coded: Material Disintegration
Patient problem as coded: Needle Stick/Puncture
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "PERLA"[tiab]. The summary above synthesizes these.
- Effect of PERLA®, a new cold-storage solution, on oxidative stress injury and early graft function in rat kidney transplantation model.
Bejaoui M, Slim C, Peralta C, et al. · BMC Nephrol · 2024Research Support, Non-U.S. Gov't
- Perla Bautista Sanchez.
Ruiz CB · Philipp J Nurs · 1975Biography, Historical Article
- Antihypertensive Effect of Perla and Esmeralda Barley (Hordeum vulgare L.) Sprouts in an Induction Model with L-NAME In Vivo.
García-Castro A, Román-Gutiérrez AD, Guzmán-Ortiz FA, et al. · Metabolites · 2024
- Bayesian mapping of mortality clusters.
Sottosanti A, Bovo E, Belloni P, et al. · Biostatistics · 2025Research Support, Non-U.S. Gov't
- Microbiological and toxicological effects of Perla black bean (Phaseolus vulgaris L.) extracts: in vitro and in vivo studies.
Lara-Díaz VJ, Gaytán-Ramos AA, Dávalos-Balderas AJ, et al. · Basic Clin Pharmacol Toxicol · 2009
- Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC.
Lim SM, Ortega Granados AL, Pinto GDJ, et al. · JTO Clin Res Rep · 2025
- "La Perla Del Mar": A Case Report on Subcutaneous Penile Implants.
Ramirez JC, Wickremasinghe PD, Mayol-Velez LX, et al. · Cureus · 2023Case Reports
- Protemblemaria perla, a new species of tube blenny (Perciformes: Chaenopsidae) from the tropical eastern Pacific.
Hastings PA · Rev Biol Trop · 2001Comparative Study, Research Support, U.S. Gov't, Non-P.H.S.
- Total Phenols and Flavonoids in Germinated Barley Using Different Solvents.
García-Castro A, Román-Gutiérrez AD, Castañeda-Ovando A, et al. · Chem Biodivers · 2023
- Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial.
Lim SM, Peters S, Ortega Granados AL, et al. · Nat Commun · 2023Randomized Controlled Trial, Clinical Trial, Phase II
- Overview of the Caucasian Perla Geoffroy, 1762 (Plecoptera: Perlidae) based on morphological and molecular data with description of two new species.
Teslenko VA, Palatov DM, Semenchenko AA · Zootaxa · 2024
- Virtual Reality for PEripheral Regional Anesthesia (VR-PERLA Study).
Alaterre C, Duceau B, Sung Tsai E, et al. · J Clin Med · 2020
Other devices of this type
Also filed under product code NKG.
- M.U.S.T. MINI Posterior Cervical Screws System ExtensionMedacta International S.A. · 510(k) 2022
- Infinity OCT SystemMedtronic Sofamor Danek USA, Inc. · 510(k) 2026
- SYMPHONY OCT SystemMedos International SARL · 510(k) 2023
- QUARTEX® Occipito-Cervico-Thoracic Spinal System ExcelsiusGPS® InstrumentsGlobus Medical, Inc. · 510(k) 2024
- Centurion POCT SystemOrthofix, Inc. · 510(k) 2020
- Yukon OCT Spinal SystemK2m, Inc. · 510(k) 2020
- Connector SystemOrthofix, Inc. · 510(k) 2019
- Proficient® Posterior Cervical Spine SystemSpine Wave, Inc. · 510(k) 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.